CALL FOR PAPERS
SPECIAL ISSUE: GLOBAL PHARMACEUTICAL LAW AND POLICY
Submission Deadline: 16 October 2020
Publication: 21 December 2020

The European Pharmaceutical Law Review (EPLR) is seeking original research papers for a special issue on global pharmaceutical law and policy.

The production and marketing of pharmaceuticals is a global business and, therefore, in this special issue, the EPLR will look beyond the territorial and jurisdictional border of the European Union to important pharmaceutical markets like: US, Canada, China, Korea, Japan, Russia, Middle East, Brazil, Mexico, Switzerland and Australia.

The aim is to assess how EU pharma law and policy influences the regulatory frameworks in third countries. Moreover, it will examine how legal and regulatory developments in third countries impact on pharmaceuticals on the internal market. How does the globalized pharmaceutical market challenge regulators in the EU and elsewhere? How to ensure quality and safety of medicines manufactured globally? Which regulatory hurdles are importing and exporting pharmaceutical companies facing? What are the benefits and downsides of regulatory cooperation and does it work in practice?

This Special Issue will be guest edited by Els Janssens, Counsel at Baker McKenzie and member of the EPLR Editorial Board, together with the EPLR Managing Editor Dr. Sabrina Röttger-Wirtz (Maastricht University).

We welcome submissions, especially on the following topics:

- Comparison of regulatory frameworks (EU and other regions), for example in the area of: accelerated approvals, regenerative medicine and stem cell research, medical cannabis
- Supply chain: manufacturing, distribution, import and export of pharmaceuticals
- Bilateral/Multilateral Regulatory Cooperation as well as Mutual Recognition Agreements
- Impact of EU pharmaceutical law on other countries (for example: biosimilars or pharmacovigilance)
- Pharmaceutical law and policy in non-EU markets (especially comparative analysis with EU)
- Comprehensive overviews of the regulatory systems in major markets like e.g. China, Russia, Brazil, Canada, Mexico
- Medicines assessed under Article 58
- International organizations and their impact on EU pharma law and policy
- Policies regarding medicines accessibility and drug shortages in a globalized market
- TRIPS and compulsory licensing
- Clinical trials and genetic research (for example human sample collection, import and export, biobanking, GCP and access to treatments)
- IP and regulatory exclusivities: protecting innovation on a global market

All contributions will be subject to double blind peer-review before acceptance for publication and are required to conform to the author guidelines available at: www.lexxion.eu/eplr/author-guidelines

Submission deadline >> 16 October 2020

The editorial team looks forward to discussing your proposals and receiving your submissions. For further enquiries, please contact the

Executive Editor:
Jakob McKernan
mckernan@lexxion.eu
+49-30-81 45 06-10